Skip to content

Avanos Medical AVNS Stock-Based Comp

Stock-Based Comp at other companies

Stryker logo
StrykerSYK
$87M+3.6%
Cardinal Health logo
Cardinal HealthCAH
$129M+316%
Boston Scientific logo
Boston ScientificBSX
$83M+12.2%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$13.54M-7.0%
Medtronic logo
MedtronicMDT
$95M+6.7%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$10.88M-5.6%

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's stock-based comp?
Avanos Medical (AVNS) reported stock-based comp of $3.7M in Q1 2026.
How has Avanos Medical's stock-based comp changed year-over-year?
Avanos Medical's stock-based comp decreased by 2.6% year-over-year, from $3.8M to $3.7M.
What is the long-term trend for Avanos Medical's stock-based comp?
Over 4 years (2021 to 2025), Avanos Medical's stock-based comp has grown at a -1.2% compound annual growth rate (CAGR), from $13.2M to $12.6M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.